This protocol applies to acute dacryocystitis in which the causative organism is methicillin-resistant Staphylococcus aureus (MRSA). MRSA occurs with notable frequency in acute dacryocystitis and cannot be adequately managed with standard antibiotic coverage.
The identification of MRSA substantially changes the antibiotic strategy required — conventional choices are not sufficient in this setting.
The protocol includes MRSA-targeted systemic antibiotic therapy — covering both oral and intravenous combination options — paired with adjunctive topical ocular treatment. Which combination applies, and under what clinical conditions, is specified in the full regimen.
DOI: 10.1007/s11908-012-0238-8
We must also recall the greater frequency of methicillin-resistant S. aureus (MRSA), specially in those patients with acute dacryocystitis.
Linezolid 600 mg/12 h + Rifampin 300 mg/12 h
Vancomycin 1 g/12 h + Linezolid 600 mg/12 h
Chloramphenicol 1/8 h
View source ↗